Drug Type TCR therapy |
Synonyms |
Target- |
Mechanism Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization PACT Pharma, Inc.Startup |
Active Organization PACT Pharma, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bladder Cancer | Preclinical | US | PACT Pharma, Inc.Startup | 21 Jul 2022 |
Breast Cancer | Preclinical | US | PACT Pharma, Inc.Startup | 21 Jul 2022 |
Colorectal Cancer | Preclinical | US | PACT Pharma, Inc.Startup | 21 Jul 2022 |
Head and Neck Neoplasms | Preclinical | US | PACT Pharma, Inc.Startup | 21 Jul 2022 |
Lung Cancer | Preclinical | US | PACT Pharma, Inc.Startup | 21 Jul 2022 |
Melanoma | Preclinical | US | PACT Pharma, Inc.Startup | 21 Jul 2022 |
Ovarian Cancer | Preclinical | US | PACT Pharma, Inc.Startup | 21 Jul 2022 |
Prostatic Cancer | Preclinical | US | PACT Pharma, Inc.Startup | 21 Jul 2022 |